Leerink Partnrs Has Bearish Outlook for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings of ($3.80) per share for the year, down from their previous forecast of ($2.85). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($5.00) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($2.45) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same period last year, the company earned ($0.73) earnings per share.

A number of other equities research analysts have also recently weighed in on XENE. Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Raymond James reissued an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $56.00.

Xenon Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ:XENE opened at $39.98 on Friday. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99. The company has a market cap of $3.05 billion, a PE ratio of -14.18 and a beta of 1.20. The company’s 50-day moving average price is $40.28 and its 200 day moving average price is $40.79.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently bought and sold shares of the business. Loomis Sayles & Co. L P increased its stake in Xenon Pharmaceuticals by 7.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company’s stock valued at $27,843,000 after buying an additional 46,964 shares during the last quarter. Vestal Point Capital LP raised its stake in Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock valued at $32,480,000 after purchasing an additional 300,000 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Xenon Pharmaceuticals by 4.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company’s stock valued at $17,287,000 after purchasing an additional 17,953 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after acquiring an additional 905,129 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Xenon Pharmaceuticals by 1,275.5% during the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $590,000 after acquiring an additional 13,903 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Insider Activity at Xenon Pharmaceuticals

In related news, CFO Sherry Aulin sold 18,709 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,383 shares of company stock worth $2,535,891 in the last ninety days. 5.52% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.